Sign inCreate account

Report workspace tools

NCT04900428TERMINATEDanonymous

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19

Sponsor

Source record

Sorrento Therapeutics, Inc.

Phase

Source record

PHASE2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

COVI-DROPS, Placebo

Indication / condition

AI-normalized

Covid19

Intervention

Source record

COVI-DROPS, Placebo

Source & freshness

Source record

NCT ID

NCT04900428

Original source

ClinicalTrials.gov

Source last updated

Jan 30, 2023

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04900428

Title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19

Sponsor

Sorrento Therapeutics, Inc.

Status

TERMINATED

Phase

PHASE2

Condition raw

Covid19

Condition normalized

Covid19

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

COVI-DROPS, Placebo

Target normalized

COVI-DROPS, Placebo

Interventions

COVI-DROPS, Placebo

Public preview

Source record

This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04900428

Status

TERMINATED

Phase

PHASE2

Sponsor

Sorrento Therapeutics, Inc.

Executive brief

Investment-Ready Snapshot

This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 30, 2023
Internal syncJun 09, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04900428

Indication

Covid19

Modality

monoclonal antibody

Target

COVI-DROPS, Placebo

Intervention

COVI-DROPS, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.